Oncotelic

Oncotelic is a clinical stage biotechnology company advancing therapies for cancer and other serious diseases by addressing the real reasons most drugs fail in the clinic. We do not build fragile single asset stories. We operate a partnership and joint venture driven model designed to accelerate development, manage risk intelligently, and create clear paths to value. We are biology first, execution driven, and grounded in clinical reality. Too many promising therapies fail not because the science is wrong, but because execution is incomplete. We see cancer treatments break down due to immune suppression, fibrosis, poor tissue penetration, resistance mechanisms, and delivery limitations. When these challenges are compounded by long development timelines, capital inefficiency, and unclear exit pathways, innovation stalls and opportunity is lost for patients and investors alike. The industry does not need more speculative targets. It needs clinically validated biology, smarter delivery, and disciplined execution. What sets Oncotelic apart? • We advance TGFB2 based therapeutics targeting a master regulator of tumor immune evasion, fibrosis, and treatment resistance, with programs progressed into late stage clinical development through strategic joint ventures • We build through Sapu Therapeutics, our majority owned joint venture combining TGFB2 programs with next generation molecular nanomedicine and a defined Hong Kong IPO pathway • We develop ultra small molecular nanomedicine technology designed for deep tissue penetration, improved pharmacology, and differentiated clinical performance • We created PDAOAI, a patented AI driven evidence interrogation platform that enables hypothesis generation, biomarker discovery, and translational insight • We operate a capital efficient partnership model that creates multiple shots on goal while preserving clinical rigor and investor clarity Oncotelic’s mission is to transform how hard to treat diseases are addressed by aligning b